OPTH

Optimi Health Corp

5.13

Sep 15 • 3:59 PM ET +0.37 (7.77%)

5.07

Aftermarket • 4:04 PM ET -0.06 (-1.17%)

Healthcare Drug Manufacturers - Specialty & Generic Canada Nano NASD

Peers: ANIK LFCR EBS PCRX EOLS HROW TKNO ANIP INDV HRMY

| Held by: PSIL

Scroll to Statements

Index	-
Market Cap	29.39M
Enterprise Value	23.81M
Income	-2.96M
Sales	0.39M
Book/sh	2.17
Cash/sh	1.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	May 20, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	75.37
P/B	2.36
P/C	3.19
P/FCF	-
EV/EBITDA	-
EV/Sales	61.06
Quick Ratio	1.69
Current Ratio	1.73
Debt/Eq	0.29
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.93
EPS next Y	-
EPS next Q	-0.13
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	27.91% -72.14%
Sales past 3/5Y	68.99% -
EPS Y/Y TTM	34.45%
Sales Y/Y TTM	61.11%
EPS Q/Q	-842.19%
Sales Q/Q	137.27%
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-43.14% -34.88%

Insider Own	19.32%
Insider Trans	0.00%
Inst Own	7.75%
Inst Trans	33.48%
ROA	-27.66%
ROE	-43.87%
ROIC	-23.59%
Gross Margin	-324.40%
Oper. Margin	-824.18%
Profit Margin	-751.47%
SMA20	6.76%
SMA50	7.40%
SMA200	-17.10%
Trades

Shs Outstand	5.73M
Shs Float	4.62M
Short Float	0.21%
Short Ratio	0.13
Short Interest	0.01M
52W High	8.84 -41.96%
52W Low	4.00 28.25%
Volatility	10.13% 5.51%
ATR (14)	0.33
RSI (14)	58.65
Beta	1.29
Rel Volume	1.70
Avg Volume	73.15K
Volume	124,374

Perf Week	5.99%
Perf Month	7.10%
Perf Quarter	6.65%
Perf Half Y	-10.59%
Perf YTD	-25.13%
Perf Year	-11.26%
Perf 3Y	21.36%
Perf 5Y	-65.80%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	4.76
Price	5.13
Change %	7.77%

Sep-10-26 08:45AM	Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder (GlobeNewswire)
Sep-08-26 08:30AM	Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-31-26 10:12AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-17-26 03:26PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-14-26 04:55PM	Optimi Health Establishes Discretionary Equity Facility (GlobeNewswire)
08:54AM	Loading…
Aug-10-26 08:54AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-06-26 03:53PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jun-29-26 11:13AM	Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression (PR Newswire) +8.80%
Jun-16-26 12:36PM	Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research (PR Newswire) -12.89%
Jun-15-26 11:28AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +5.71%
Jun-10-26 02:24PM	Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial (PR Newswire)
Jun-08-26 02:41PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +11.21%
12:54PM	Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development (PR Newswire)
Jun-02-26 07:30AM	Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia (GlobeNewswire)
May-29-26 03:30PM	Optimi Health (OPTH) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update (NewMediaWire) +5.58%
11:14AM	Loading…
11:14AM	Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia (PR Newswire)
May-26-26 07:00AM	Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date (Newsfile Corp.)
May-21-26 01:42PM	SRx Health Decided To Invest In A Psychedelic Drug Company That Just Went Public Heres What Aided The Decision (Stocktwits) -6.25%
01:07PM	Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering (Newsfile Corp.)
May-20-26 11:30AM	Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting (PR Newswire) -13.83%
08:00AM	Optimi Health gibt Preisfestsetzung fur uberzeichnetes offentliches Angebot in Hohe von 15 Mio. US-$ und Nasdaq-Uplisting bekannt (Newsfile)

Optimi Health Corp. functions as an end-to-end GMP manufacturer and supplier of psychedelic substances. It offers formulation, active pharmaceutical ingredients (APIs), and drug product manufacturing from preclinical stages to analysis and commercial distribution and It also offers botanical psilocybin and MDMA. The company was founded on May 27, 2020 and is headquartered in Squamish, Canada.

Co-Founder & ChairmanMr. John James Wilson

Co-FounderMr. Dane Stevens

Co-FounderMr. Bryan Edward Safarik

Interim CFO & DirectorMr. Jacob Safarik

Chief Science OfficerDr. Preston A. Chase

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OPTH

Optimi Health Corp

Upgrade your Finviz experience